RxDoctor Payments Data

Hao Tran, MD

Advanced Heart Failure and Transplant Cardiology · San Diego, CANPI 1891997078

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (47.9%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 22 manufacturers reported payments, led by Abbott at 48.9% of the total. Reporting peaked in 2024 at $48,648 and has fallen 69.2% since, to $14,964 in 2025.

$146,831in general payments, 2019–2025

Across 311 payments — averaging $472.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$72K
  • Abiomed$71K
  • Medtronic$669
  • Impulse Dynamics (USA) Inc.$510
  • Boston Scientific$407
  • Kestra Medical Technology Services, Inc.$392
  • plus $2K from 16 others
$172,261in research payments, 2019–2025

Across 26 payments — averaging $6625.41 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Endotronix, Inc.$157K
  • Alnylam Pharmaceuticals Inc.$15K

What the payments were for

  • Consulting fees$45,79031%
  • Speaking & faculty fees$70,33348%
  • Travel & lodging$17,23212%
  • Food & beverage$13,4779%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$146,831 in reported general payments places this provider in the 80th percentile of 111 advanced heart failure and transplant cardiology providers in California.

See all advanced heart failure and transplant cardiology providers in California

Medicare billing

Part B allowed, 2024
$106,969
Medicare patients
567
Services billed
1,344

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan119$118,015
JardianceEmpagliflozin91$74,486
EliquisApixaban35$20,909
FarxigaDapagliflozin Propanediol21$19,478
Sirolimus19$13,063
DapagliflozinDapagliflozin Propanediol13$5,403
Tacrolimus23$4,652
Bumetanide66$2,956
Valganciclovir Hcl11$2,905
Warfarin Sodium117$1,185
Metoprolol Succinate62$872
Rosuvastatin Calcium79$839
Torsemide32$798
Spironolactone71$775
Potassium Chloride34$741

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$12$118,015119 claims
Boehringer IngelheimJardiance$384$74,48691 claims
PfizerEliquis$15$20,90935 claims
AstraZenecaFarxiga$141$19,47821 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 111 advanced heart failure and transplant cardiology providers in California.

Other advanced heart failure and transplant cardiology in San Diego

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →